

June, 2009

NANCY L. GELLER

Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockledge Centre 2 Suite 9093, 6701 Rockledge Dr. MSC 7913, Bethesda, MD 20892-7913. Phone (301) 435-0434; FAX (301) 480-1862; e-mail: ng@helix.nih.gov.

EDUCATION

The City College of New York, B.S., 1965, Mathematics.
Case Institute of Technology, M.S., 1967, Mathematics.
Case Western Reserve University, Ph.D., 1972, Mathematics.

EMPLOYMENT

1970-1972: Instructor to Assistant Professor, Department of Statistics, University of Rochester, Rochester, NY.
1972-1978: Assistant Professor, Department of Statistics, University of Pennsylvania, Philadelphia, PA.
1978-1979: Associate Professor of Statistics, Department of Community and Preventive Medicine, The Medical College of Pennsylvania, Philadelphia, PA.
1979-1990: Assistant to Associate Member, Division of Biostatistics, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center (MSKCC), NY; Assistant to Associate Professor of Biostatistics, Cornell University Graduate School of Medical Sciences, NY.
1984-1985: American Cancer Society Scholar, Department of Epidemiology and Clinical Practice, The Royal Free Hospital School of Medicine, London, England.
March, 1987 - July, 1989: Acting Head of Division of Biostatistics, MSKCC.
1990-present: Chief, Biostatistics Research Branch; then Director, Office of Biostatistics Research, National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health, Bethesda, MD.

GRANT SUPPORT AND HONORS

1961-1965: New York State Scholarship, The City College of New York.
1965-1970: N.S.F. Traineeship and University Fellowship, Case Institute/ Case Western Reserve U.
1984-1985: American Cancer Society Scholar Award.
1985-1990: Co-Principal Investigator, Cancer Chemotherapy Program Project Grant (Biostatistics Core), N.I.H. CA 05826, Memorial Hospital.
1986-1990: Principal Investigator, "Statistical methods for cancer clinical trials," NIH CA 43074
1987: Donald B. Franke Award (with S. Pocock), Drug Information Association for publication of an outstanding original article.
1993: NIH Merit Award (for exceptional performance of statistical collaboration in the clinical research programs of NHLBI).
1993: Fellow, American Statistical Association.
1993-1996: Member, Executive Committee; 1996-1998: President-Elect; 1999-2000: President, 2001: Ex-President, International Society for Clinical Biostatistics.
1997-1999: Member, Spiegelman Award Committee, American Statistical Association.
2000-2002: Member, Elizabeth L. Scott Award Committee of Presidents of Statistical Societies, Chair, 2002.
2010: President-Elect, American Statistical Association.

PROFESSIONAL AFFILIATIONS

American Statistical Association; the Biometric Society; Institute of Mathematical Statistics; International Society for Clinical Biostatistics; Society for Clinical Trials.

TEACHING EXPERIENCE

Calculus; Introductory probability and statistics; Nonparametric statistics (graduate course); Probability (graduate course); Sequential decision analysis (graduate course); Biostatistics (medical and graduate students); various lectures on clinical trials methodology to statisticians and doctors.

PROFESSIONAL ACTIVITIES

Graduate students, Post-doctoral fellows, other mentoring

Dei-In Tang, Post-doctoral fellow, 1987-1988.

Zhaohai Li, Post-doctoral fellow, 1989-1990.

Clare Gnecco, Ph.D. student (Ph.D. 1991, Polytechnic University, NY.).

Craig Borkowf, National Research Council Post-doctoral fellow, 1997-1999.

Summer trainees 2002: Angela Nistetter (undergraduate, Texas A & M University), 2003: Veena Shetty (master's student, University of Oklahoma), 2004: Nicole Bohme (undergraduate, St. Olaf's College), 2005: Chelsea Ellis (master's student, University of Florida), 2006: Sarah Karl (undergraduate, Central Michigan University), 2007: Haley Hedlin (Ph.D. student, Johns Hopkins University), 2008: Lauren Kunz (St. Olaf's College, B.S. 2008).

Recent seminars and invited meetings (since 2003)

March, 2003: Multiple endpoints in clinical trials, Medical University of South Carolina.

April, 2003: Multiple endpoints in clinical trials, Virginia Commonwealth University.

May, 2003: Multiple endpoints in clinical trials. Special invited speaker at Annual Case Western Reserve University/Cleveland Clinic Foundation/Ohio State University Joint Biostatistics Symposium.

August, 2003: A hybrid frequentist-Bayesian approach to design of early trials with application to peripheral blood stem cell transplantation. Invited speaker at session on Adaptive Designs, International Statistical Institute, Berlin, Germany.

December, 2003: Dilemmas in monitoring clinical trials. Keynote speaker at the 10th annual Biopharmaceutical Applied Statistics Symposium, Savannah, Georgia.

December, 2005: Invited speaker at Cardiovascular Clinical Trials Workshop 8: Covariate analysis: why and how to do it, Versailles, France.

December, 2006: Invited discussant at Cardiovascular Clinical Trials Workshop 9: Under what circumstances should the DSMB share interim trial data with investigators/government-industry sponsors? Paris, France.

December, 2007: Leader for breakout session on controversies on Data and Safety Monitoring Boards, Cardiovascular Clinical Trials Workshop 10, Paris, France.

April, 2008: Invited participant in Cardiovascular Clinical Trial Think Tank, Chicago, Illinois.

Other recent professional activities

1989- : Associate Editor, Biometrics

1999-2002: Member Gastrointestinal Drugs Advisory Committee, Food and Drug Administration.

2000-2002: Member Elisabeth Scott Award Committee of the Committee of Presidents of Statistical Societies. Chair, 2002.

2003- : Member of Editorial Board, Clinical Trials

2007: Member, Food and Drug Administration panel assessing the safety of Rosiglitazone.

Referee for (selection): American Journal of Epidemiology, Biometrics; Biometrika; Communications in Statistics, Controlled Clinical Trials; Journal of the American Statistical Association; Journal of Biopharmaceutical Statistics, Statistics in Medicine, Stroke.

RECENT ACTIVITIES WHILE AT NHLBI (since 2000)

Clinical Trials

Participated in design, implementation and monitoring of multi-center clinical trials:

Action to Control Cardiovascular Risk in Diabetes (ACCORD).

Atrial Fibrillation Follow-up of Rhythm Management (AFFIRM).

Azithromycin and Coronary Events Study (ACES).

Bone Marrow Transplantation Clinical Trials Network.

Cardiothoracic Clinical Trials Network.

Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM).

Inhaled Nitric Oxide in premature infants.

Prevention of Events with ACE inhibition in coronary disease patients with preserved left ventricular function (PEACE).

Randomized trial of genotype-guided dosing of Warfarin therapy.

Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS).

Women's Health Initiative (WHI).

Committees and Other Activities

1994- present: Member, Biostatistics/Epidemiology (Tenure and Promotions) Review Panel, NIH;

1997- present: Member of Institute Scientific Review Committee (scientific review of intramural clinical trials);

1999: Member of NCI search committee for senior biostatistician;

2004-present: Member of Data and Safety Monitoring Board for Frequent Hemodialysis Network, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health;

2005: Chair, search committee for NICHD tenure track or tenured biostatistician;

2008: Member, search committee for NIDA tenure track or tenured computational biologist/bioinformaticist.

PUBLISHED PAPERS

Dudewicz, E.J. and Geller, N.L. (1972). Book review of Nonparametric Statistical Inference by Jean Dickinson Gibbons. Journal of the American Statistical Association 67:962-963.

Geller, N.L. (1972). On distributions of some Kolmogorov-Smirnov type statistics. Case Western Reserve University. (Ph.D. thesis.)

Geller, N.L. and Yochmowitz, M.G. (1975). Regional planning of maternity services. Health Services Research Spring:63-75.

Geller, N.L. (1977). On limit distributions for one- and two-sample Kolmogorov-Smirnov type statistics. Journal of Applied Probability 14:538-547.

Geller, N.L., De Cani, J.S. and Davies, R.E. (1978). Lifetime-citation rates to compare scientists' work. Social Science Research 7:345-365.

Geller, N.L. (1978). Some examples of the weak and strong laws of large numbers for averages of mutually independent random variables. The American Statistician 32:34-36.

- Geller, N.L., Gensler, R., Hafer, E., Hohwald, J., Kingsbury, L., Rosen, A., Siler, J., Sugiarto, X. and Szabat, K. (1978). Four combinatorial probability problems. The Pentagon 1-8.
- Geller, N.L. (1978). On the citation influence methodology of Pinski and Narin. Information Processing and Management 14:93-95.
- Geller, N.L. (1979). A test of significance for the Whitworth distribution. Journal of the American Society of Information Science 30:229-231.
- Clarke, J.R., Davidson, S.J., Bergman, G.E. and Geller, N.L. (1980). Optimal blood ordering for emergency department patients. Annals of Emergency Medicine 9:26.
- Day, N.K., Witkin, S.S., Sarkar, N.H., Kinne, D., Jussawalla, D.J., Levin, A., Hsia, C.C., Geller, N. and Good, R.A. (1981). Antibodies reactive with murine mammary tumor virus in sera of patients with breast cancer: Geographic and family studies. Proceedings of the National Academy of Sciences of the U.S.A. 78:2483-2487.
- Geller, N.L., De Cani, J.S. and Davies, R.E. (1981). Lifetime-citation rates: A mathematical model to compare scientists' work. Journal of the American Society of Information Science 32:3-15.
- Iwata, T., Incefy, G.S., Cunningham-Rundles, S., Cunningham-Rundles, C., Smithwick, E., Geller, N., O'Reilly, R. and Good, R.A. (1981). Circulating thymic hormone activity (FTS) in patients with primary and secondary immunodeficiency diseases. The American Journal of Medicine 71:385-394.\
- Oberst, M.T., Graham, D., Geller, N.L., Stearns, M.W., Jr. and Tiernan, E. (1981). Catheter management programs and postoperative urinary dysfunction. Research in Nursing and Health 4:175-181.
- Besa, E.C., Nowell, P.C., Geller, N.L. and Gardner, F.H. (1982). Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival. Cancer 49:308-313.
- Cohen, J., Kuchta, N., Geller, N., Shires, T. and Dineen, P. (1982). Pancreaticoduodenectomy A 40 year experience. Annals of Surgery 195:608-617.
- Katopodis, N., Hirshaut, Y., Geller, N.L. and Stock, C.C. (1982). Lipid-associated sialic acid test for the detection of human cancer. Cancer Research 42:5270-5275.
- Witkin, S.S., Zelikovsky, G., Bongiovanni, A.M., Geller, N., Good, R.A. and Day, N.K. (1982). Sperm-related antigens, antibodies and circulating immune complexes in sera of recently vasectomized men. Journal of Clinical Investigation 70:33-40.
- Bosl, G.J., Geller, N., Cirrincione, C., Hajdu, S.I., Whitmore, W., Nisselbaum, J., Vugrin, D. and Golbey, R.B. (1983). Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis. Cancer 51:2121-2125.
- Bosl, G.J., Geller, N., Cirrincione, C., Vogelzang, N.J., Kennedy, B.J., Whitmore, W.F., Vugrin, D., Scher, H., Nisselbaum, J. and Golbey, R.B. (1983). Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Research 43:3403-3407.
- Bosl, G., Geller, N.L., Cirrincione, C., Nisselbaum, J., Vugrin, D., Whitmore, W.F. and Golbey, R.B. (1983). Serum tumor markers in patients with metastatic germ cell tumors of the testis: A ten-year experience. The

American Journal of Medicine 75:29-35.

Cohen, J.R., Kuchta, K., Geller, N., Shires, G.T. and Dineen, P. (1983). Pancreaticoduodenectomy for benign disease. Annals of Surgery 197:68-71.

Geller, N.L. (1983). Statistical strategies for animal conservation. Annals of the New York Academy of Sciences 406:20-31.

Pollack, S., Micali, A., Kinne, D.W., Enker, W.E., Geller, N., Oettgen, H.F. and Hoffman, M.K. (1983). Endotoxin-induced in vitro release of interleukin-1 by cancer patients' monocytes: Relation to stage of disease. International Journal of Cancer 32:733-736.

Scher, H., Bosl, G., Geller, N.L., Cirincione, C., Whitmore, W., Jr. and Golbey, R. (1983). Impact of symptomatic interval on prognosis of patients with Stage III testicular cancer. Urology 21:559-561.

Geller, N.L. (1984). Design of Phase I and II clinical trials in Cancer: a statistician's view. Cancer Investigation 2:483-491.

Kemeny, N., Daly, J., Oderman, P., Shike, M., Chun, H., Petroni, G. and Geller, N.L. (1984). Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. Journal of Clinical Oncology 2:595-600.

Thongprasert, S., Bosl, G.J., Geller, N.L. and Wittes, R.E. (1984). Phase II trial of mitoguazone in patients with advanced head and neck cancer. Cancer Treatment Reports 68:1301-1302.

Ahmed, T., Yagoda, A., Needles, D., Scher, H.I., Watson, R.C. and Geller, N. (1985). Vinblastine and methotrexate for advanced bladder cancer. Journal of Urology 133:602-604.

Amorosa, J.K., Geller, N.L., Harrigan, W.D. and Saxanoff, S. (1985). Integration of the Diagnostic Radiological Health Sciences Learning Laboratory Films into a radiology elective for medical students. Investigative Radiology 20:543-545.

Fein, R., Kelsen, D.P., Geller, N., Brennan, M. and Martini, N. (1985). Adenocarcinoma of the esophagus and gastro-esophageal junction: Prognostic factors and results of therapy. Cancer 56:2512-2518.

Geller, H.M., Geller, N.L., Krespan, B. and Cooperstein, R. (1985). Statistical analysis of temperature-dependent neuronal activity. Journal of Neuroscience Methods 14:127-136.

Jain, K.K., Casper, E.S., Geller, N.L., Hakes, T.B., Kaufman, R.J., Currie, V., Schwartz, W., Cassidy, C., Petroni, G., Young, C.W. and Wittes, R.E. (1985). Prospective randomized comparison of doxorubicin and a less cardiotoxic analog, epirubicin, in patients with advanced breast cancer. Journal of Clinical Oncology 3:818-826.

Leitner, S.P., Casper, E.S., Hakes, T.B., Kaufman, R.J., Winn, R.J., Scoppetuolo, M., Raymond, V., Geller, N.L. and Young, C.W. (1985). Phase II trial of 4' Deoxydoxorubicin in patients with advanced breast cancer. Cancer Treatment Reports 69:1319-1320.

Pinsky, C.M., Camacho, F.J., Kerr, D., Geller, N.L., Klein, F.A., Herr, H.A., Whitmore, W.F., Jr. and Oettgen, H.F. (1985). Intravesical administration of Bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: Report of a prospective, randomized trial. Cancer Treatment Reports 69:47-53.

Stanton, G.F., Raymond, V., Wittes, R.E., Schulman, P., Budman, D., Baratz, R., Williams, L., Petroni, G.R., Geller, N.L., Hancock, C., Kreis, W. and Young, C.W. (1985). Phase I and clinical pharmacologic evaluation of 4'-Deoxydoxorubicin in patients with advanced cancer. Cancer Research 45:1862-1868.

Sternberg, C., Yagoda, A., Scher, H.I., Watson, R.C., Ahmed, T., Weiselberg, L.R., Geller, N., Hollander, P.S., Herr, H.W., Sogani, P.C., Morse, M.J. and Whitmore, W.F. (1985). Preliminary results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for transitional cell carcinoma of the urothelium. Journal of Urology 133:403-407.

Bosl, G.J., Gluckman, R., Geller, N.L., Golbey, R.B., Whitmore, W.F., Herr, H., Sogani, P., Morse, M., Martini, N., Bains, M. and McCormack, P. (1986). VAB-6: An effective chemotherapy regimen for patients with germ cell tumors. Journal of Clinical Oncology 4:1493-1499.

Gail, M.H., Muenz, L., Mcintire, K.R., Radovich, B., Braunstein, G., Brown, P.R., Deftos, L., Dnistrian, A., Dunsmore, M., Elashoff, R., Geller, N., Go, V.L., Hirji, K., Klauber, M.R., Pee, D., Petroni, G., Schwartz, M. and Wolfson, A.R. (1986). Multiple markers for lung cancer diagnosis: validation of models for advanced lung cancer. Journal of the National Cancer Institute 76:805-816.

Pocock, S.J. and Geller, N.L. (1986). Interim analyses in randomized clinical trials. Drug Information Journal 20:263-269.

Redman, J.R., Saigo, P.E., Petroni, G.R., Geller, N.L. and Hakes, T.B. (1986). Prognostic factors in ovarian carcinoma. Journal of Clinical Oncology 4:515-523.

Smith, J.L. (with the N.Y. Academy of Sciences Ad Hoc Committee on Animal Research, including N.L. Geller). (1986). Interdisciplinary principles and guidelines for the use of Animals in Research, Testing, and Education. New York, The New York Academy of Sciences.

Tauer, K., Kemeny, N., Cheng, E., Hollander, P. and Geller, N. (1986). Phase II trial of N-Methyl Formamide (NMF) in patients with advanced colorectal carcinoma. Cancer Treatment Reports 70:813-814.

Bosl G.J., Bajorin, D. and Geller, N.L. (1987). An analysis of poor risk assignment in patients with germ cell tumours. International Journal of Andrology 10:285-289.

Bosl, G.B., Bajorin, D. and Geller, N.L. (1987). An analysis of poor risk assignment in patients with germ cell tumors. In: Cancer in situ and cancer of the testis, Rith, Grigor, Daugnard, et al., ed. Blackwell Scientific Publishers, NY 285-288.

Bosl G.J., Geller N.L., Vogelzang N.J., Carey R., MacDonald G. and Chan E. (1987). Alternating cycles of etoposide + cisplatin and VAB-6 in the treatment of poor risk patients with germ cell tumors. Journal of

Clinical Oncology 5:436-440.

Fiore, J.J., Kemeny, N., Mehta, B., Geller, N., Grossano, B.S. and Murphy, B.S. (1987). Systemic absorption of a leucovorin mouthwash: a pharmacologic study. Cancer Investigation 5:109-111.

Geller, N.L. (1987). Planned interim analysis and its role in cancer clinical trials. Journal of Clinical Oncology 5:1485-1490.

Geller, N.L. and Pocock, S.J. (1987). Interim analysis in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics 43:213-224.

Geller, N.L. and Pocock, S.J. (1987). Design and analysis of clinical trials with group sequential stopping rules. In: Handbook of Biopharmaceutical Statistics in Human Drug Development, Karl E. Peace, ed. Marcel Dekker, Inc., New York and Basel, 489-508.

Kemeny, N.E., Daly, J., Reichman, B., Geller, N., Botet, J. and Oderman, P. (1987). A randomized study of intrahepatic versus systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Annals of Internal Medicine 107:459-465.

Pocock, S.J., Geller, N.L. and Tsiatis, A.A. (1987). The analysis of multiple endpoints in clinical trials. Biometrics 43:487-498.

Scher, H.S., Curley, T., Geller, N., Heston, W., Dershaw, D., Chan, E., Nisselbaum, J., Alcock, N., Hollander, P. and Yagoda, A. (1987). Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover. Cancer Treatment Reports 71:887-893.

Scher, H.I., Geller, N.L., Muggia, F. M. and Rozenzweig, M. (1987). Clinical evaluation of anticancer treatments: Phase II clinical trials. In: Muggia, F.M. and Rozenzweig, M. eds. In: Clinical Evaluation of Antitumor Therapy, Hinkham, Martinus Nijhoff, Boston, 175-197.

Bajorin, D., Katz, A., Bosl, G.J., Chan, E.Y.W. and Geller, N.L. (1988). Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. Journal of Clinical Oncology 6:786-792.

Bosl, G.J., Geller, N.L. and Bajorin, D. (1988). Treatment of "poor risk" germ cell tumors. Seminars in Oncology 15:339-344.

Bosl, G.J., Geller, N.L., Bajorin, D., Leitner, S.P., Yagoda, A., Golbey, R.B., Scher, H., Vogelzang, N.J., Auman, J., Carey, R., Fair, W. Herr, H., Morse, M., Sogani, P. and Whitmore, W. Jr. (1988). A randomized clinical trial of etoposide + cisplatin versus vinblastine + cyclophosphamide + actinomycin D + bleomycin + cisplatin in patients with good prognosis germ cell tumors. Journal of Clinical Oncology 6:1231-1238.

Bosl, G.J., Geller, N.L. and Chan, E.Y.W. (1988). Stage migration revisited: improved prognosis of patients with advanced germ cell tumors entering clinical trials of combination chemotherapy. Cancer Research 48:3524-3527.

Gail, M.H., Muenz, L., McIntire, K.R., Radovich, B., Braunstein, G., Brown, P.R., Deftos, L., Dnistrian, A., Dunsmore, M., Elashoff, R., Geller, N., Go, V.L., Hirji, K., Klauber, M.R., Pee, D., Petroni, G., Schwartz, M. and Wolfson, A.R. (1988). Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer. Journal of the National Cancer Institute 80:97-102.

Geller, Nancy L., and Pocock, Stuart J. (1988). Design and analysis of clinical trials with group sequential stopping rules. Chapter 11 in: Biopharmaceutical Statistics for Drug Development, Karl E. Peace, ed. Marcel Dekker, Inc., New York and Basel, 489-508.

Kemeny, N.E., Reichman, B., Geller, N.L. and Hollander, P. (1988). Implementation of the group sequential methodology in a randomized trial in metastatic colorectal carcinoma. American Journal of Clinical Oncology 11:66-72.

Motzer, R., Bosl, G.J., Geller, N.L., Penenberg, D., Yagoda, A., Herr, H., Morse, M., Sogani, P., Vogelzang, N. and Carey, R. (1988). Advanced seminoma: the role of chemotherapy and adjunctive surgery. Annals of Internal Medicine 108:513-518.

Scher, H.I., Shank, B., Chapman, R., Geller, N., Pinsky, C., Gralla, R., Kelsen, D., Bosl, G., Golbey, R., Petroni, G., Niedzwiecki, D., Martini, N., Heelan, R., Hollander, P., Hilaris, B., Oettgen, H. and Wittes, R.E. (1988). A randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer. Cancer Research 48:1663-1670.

Scher, H.I., Yagoda, A., Herr, H., Sternberg, C., Bosl, G., Morse, M., Sogani, P., Watson, R. Dershaw, D., Reuter, V., Geller, N., Hollander, P., Vaughn, E.D., Jr., Whitmore, W. and Fair, W. (1988). Neoadjuvant M-VAC (Methotrexate, Vinblastine, Adriamycin and Cisplatin): effect on the primary bladder lesion. Journal of Urology 139:470-474.

Sternberg, C., Yagoda, A., Scher, H.I., Watson, R.C., Herr, H.W., Morse, M.J., Sogani, P.C., Vaughan, E.D., Bander, N., Weiselberg, L.R., Geller, N.L., Hollander, P.S., Fair, W.R. and Whitmore, W.F. (1988). M-VAC (Methotrexate, Vinblastine, Adriamycin and Cisplatin) for advanced transitional cell carcinoma of the urothelium. Journal of Urology 139:461-469.

Sternberg, C.N., Yagoda, A., Scher, H.I., Watson, R.C., Herr, H.W., Morse, M.J., Sogani, P.C., Vaughan, E.D., Bander, N., Geller, N., Fair, W.R. and Whitmore, W.F. (1988). Chemotherapeutic management of invasive bladder carcinoma. European Urology (Supplement 1) 14:19-20.

Whitmore, W.F., Scher, H.I., Yagoda, A., Herr, H.W., Hollander, P.S., Sternberg, C., Bosl, G.J., Morse, M.J., Sogani, P.C., Geller, N., Watson, R.C., Dershaw, D., Reuter, V., Vaughan, E.D. and Fair, W.R. (1988). Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) for advanced, localized bladder cancer. In: Trends in Bladder Cancer Chemotherapy and New Trends in BPH Etiopathogenesis, Acta Medica, Rome, Italy, 113-120.

Bosl, G.J., Dmitrovsky, E., Reuter, V., Samaniego, F., Rodriguez, E., Geller, N.L. and Chaganti, R.S.K. (1989). i(12p): a clinically useful chromosomal marker for male germ cell tumors. Journal of the National Cancer Institute 81:1874-1878.

Bosl, G.J. and Geller, N.L. (1989). The management of nonseminomatous germ cell tumors at Memorial Sloan-Kettering Cancer Center. In Systemic Therapy for Genitourinary Malignancies Johnson, D.E., Logothetis, C.J. and von Eschenbach, A., eds., Yearbook Publishers, Chicago, Illinois, 331-337.

Geller, N.L. (1989). Discussion of "Interim analyses: the repeated confidence interval approach" by C. Jennison and B.W. Turnbull. Journal of the Royal Statistical Society B 51:345-346.

Geller, N.L., Bosl, G.J. and Chan, E.Y.W. (1989). Prognostic factors for relapse following complete response in patients with metastatic germ cell tumors. Cancer 63:440-445.

Spiro, R.H., Armstrong, J., Harrison, L., Geller, N.L., Lin S.-Y. and Strong, E.W. (1989). Carcinoma of major salivary glands: recent trends. Archives of Otolaryngology 115:316-321.

Sternberg, C., Yagoda, A., Scher, H., Watson, R., Geller, N., Herr, H., Morse, M., Sogani, P., Vaughan, D., Bander, N., Weiselberg, L., Rosado, K., Smart, T., Penenberg, D., Lin, S.-Y., Fair, W.R., and Whitmore, W. (1989). M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response. Cancer 64:2448-2458.

Tang, D.-I., Gnecco, C. and Geller, N.L. (1989). Design of group sequential clinical trials with multiple endpoints. Journal of the American Statistical Association 84:776-779.

Tang, D.-I., Gnecco, C. and Geller, N.L. (1989). An approximate likelihood ratio test for a normal mean vector with nonnegative components with application to clinical trials. Biometrika 76:577-583.

Yagoda, A., Scher, H.I., Herr, H.W., Sternberg, C.N., Reuter, V., Dershaw, D., Bosl, G.J., Morse, M.J., Sogani, P.C., Watson, R.C., Geller, N., Vaughan, E.D., Whitmore, W.R. and Fair, W.R. (1989). Phase I/II trial of neoadjuvant M-VAC for primary urothelial tract tumors. In: Systemic Therapy for Genitourinary Malignancies, Johnson D.E., Logothetis, C.J., von Eschenbach, A.C., eds. Yearbook Medical Publishers Co., Chicago, 85-93.

Freedman, L., Javadpour, N., Sylvester, R., Aso, Y., Debruyne, F.M.J., Fossa, S.D., Geller, N., Horwich, A., Levine, L., Mostofi, F.K., Murphy, G.P., Simon, R., Stenning, S.P. and Stoter, G. (1990). Basic principles of clinical trials as applied to testicular cancer. Progress in Clinical and Biological Research 357:255-66.

Geller, N.L. (1990). Design of Phase I and II trials in cancer. Drug Information Journal 24:341-349.

Geller, N.L., Hakes, T.B., Petroni, G.R., Currie, V. and Kaufman, R. (1990). Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy. Cancer 66:1678-1684.

Geller, N.L., Scher, H.S., Parmar, M., Dalesio, O. and Kaye, S. (1990). Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer? Seminars in Oncology 17:628-634.

Motzer, R.J., Cooper, K., Geller, N.L., Bajorin, D.F., Dmitrovsky, E., Herr, H., Morse, M., Fair, W., Sogani, P. Russo, P. and Bosl, G.J. (1990). The role of Ifosfamide plus Cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 66:2476-2481.

Motzer, R., Cooper, K., Geller, N.L., Pfister, D.G., Lin, S.-Y., Bajorin, D., Scher, H.I., Herr, H., Fair, W., Morse, M., Sogani, P., Whitmore, W. and Bosl, G.J. (1990). Carboplatin + Etoposide + Bleomycin for patients with "poor risk" germ cell tumors. Cancer 65:2465-2470.

Motzer, R.J., Geller, N.L. and Bosl, G.J. (1990). The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good risk disseminated germ cell tumor patients. Cancer 66:857-861.

Samaniego, F., Rodriguez, E., Houldsworth, J. Murty, V.V.V.S., Ladanyi, M., Lele, K.P., Chen, Q., Dmitrovsky, E., Geller, N.L., Reuter, V., Jhanwar, S.C., Bosl, G.J. and Chaganti, R.S.K. (1990). Cytogenetic and molecular analysis of human male germ cell tumors: Chromosome 12 abnormalities and gene amplification. Genes, chromosomes and cancer 1:289-300.

Scher, H.I., Curley, T., Geller, N., Engstrom, C., Dershaw, D.D., Lin, S.-Y., Fitzpatrick, K., Nisselbaum, J., Schwartz, M., Bezerdjian, L. and Eisenberger, M. (1990). Trimetrexate in prostatic cancer: use of prostatic-specific antigen and serum acid phosphatase as markers in hormone refractory disease. Journal of Clinical Oncology 8:1830-1838.

Stoter, G., Bosl, G.J., Droz, J.P., Fossa, D., Freedman, L.S., Geller, N.L., Horwich, A., Jones, W.G., Kaye, S.B., Mead, G.M., et al. (1990). Prognostic factors in metastatic germ cell tumors. Progress in Clinical and Biological Research 357:313-319.

Toner, G.C., Geller, N.L., Tan, C. and Bosl, G.J. (1990). Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in non-seminomatous germ cell tumors. Cancer Research 50:5904-5910.

Toner, G.C., Panicek, D.M., Heelan, R.T., Geller, N.L., Lin, S.-Y., Bajorin, D., Motzer, R.J., Scher, H.I., Herr, H.W., Morse, M.J., Fair, W.R., Sogani, P.C., Whitmore, W.F., McCormack, P.M., Bains, M.S., Martini, N. and Bosl, G.J. (1990). Adjunctive surgery after chemotherapy for non-seminomatous germ cell tumors: recommendations for patient selection. Journal of Clinical Oncology 8:1683-1694.

Bajorin, D.F., Geller, N.L. and Bosl, G.J. (1991). Assessment of risk in metastatic testis carcinoma: impact on treatment. Urologia Internationalis 46:298-303.

Bajorin, D.F., Geller, N.L., Weisen, S.F. and Bosl, G.J. (1991). Two drug therapy in patients with metastatic germ cell tumors: long term follow-up. Cancer 67:28-32.

Bosl, G.J., Geller, N.L. and Bajorin, D. (1991). Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors. Cancer 67:1299-1304.

Geller, N.L., Sternberg, C.N., Penenberg, D., Chan, E.Y.W., Scher, H. and Yagoda, A. (1991). Prognostic factors for survival of patients with advanced urothelial tumors treated with M-VAC chemotherapy. Cancer 67:1525-1531.

Herr, H.W., Toner, G.C., Geller, N.L., Bosl, G.J. (1991). Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors. European Urology 19:1-5.

- Li, Z. and Geller, N.L. (1991). On the choice of times for data analysis in group sequential clinical trials. Biometrics 47:745-750.
- Motzer, R.J., Geller, N.L., Tan, C.C.-Y., Herr, H., Morse, M., Fair, W., Sheinfeld, J., Sogani, P., Russo, P. and Bosl, G.J. (1991). Salvage chemotherapy for patients with germ cell tumors The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 67:1305-1310.
- Toner, G.C., Geller, N.L., Lin, S.-Y. and Bosl, G.J. (1991). Extragonadal and poor risk non-seminomatous germ cell tumors: survival and prognostic features. Cancer 67:2049-2057.
- Follmann, D.A., Wu, M. and Geller, N.L. (1992). Issues in the analysis of clinical trials for opiate dependence. NIDA monograph, Statistical issues in clinical trials for treatment of opiate dependence, 97-113.
- Geller, N.L. (1992). Comments on efficacy of urinalysis in monitoring heroin and cocaine abuse patterns: implications in clinical trials for treatment of drug dependence. NIDA monograph, Statistical issues in clinical trials for treatment of opiate dependence, 59-61.
- Geller, N.L. and Bosl, G.J. (1992). Group sequential trial of two combination chemotherapy regimens in good risk patients with advanced germ cell tumors. Chapter 8 in: Biopharmaceutical Sequential Statistical Analysis, Karl E. Peace, ed. Marcel Dekker, Inc., New York and Basel, 155-161.
- Geller, N.L., Gnecco, C. and Tang, D.-I. (1992). Group sequential designs for trials with multiple endpoints. Chapter 3 in: Biopharmaceutical Sequential Statistical Analysis, Karl E. Peace, ed. Marcel Dekker, Inc., New York and Basel, 29-33.
- Petrylak, D.P., Scher, H.I., Li, Z., Myers, C.E. and Geller, N.L. (1992). Prognostic factors for survival of patients with bidimensionally measurable hormone refractory prostatic carcinoma treated with single agent chemotherapy. Cancer 70:2870-2178.
- The ACIP Investigators (includes N.L. Geller). (1992). Asymptomatic cardiac ischemia pilot study (ACIP): a brief description. The American Journal of Cardiology 70:744-747.
- Bajorin, D.F., Sarosdy, M., Pfister, D.G., Mazumdar, M., Motzer, R.J., Scher, H.I., Geller, N.L., Fair, W.R., Herr, H., Sogani, P., Scheinfeld, J., Russo, P., Weisen, S.F., Vlami, V., Carey, R., Vogelzang, N.J., Crawford, E.D., and Bosl, G.J. (1993). A randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good risk germ cell tumors. Journal of Clinical Oncology 11:598-606.
- Geller, N.L. and Stylianou, M. (1993). Practical issues in data monitoring of clinical trials: summary of responses to a questionnaire at N.I.H. Statistics in Medicine 12:543-552.
- Scher, H.I., Geller, N.L., Curley, T. and Tao, Y. (1993). The effect of cumulative dose intensity on survival of patients with urothelial cancer treated with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC). Journal of Clinical Oncology 11:400-407.
- Tang, D.-I., Geller, N.L. and Pocock, S.J. (1993). On the design and analysis of randomized clinical trials with multiple endpoints. Biometrics 49:23-30.
- Feuer, E.J., Frey, C.M., Brawley, O., Nayfield, S., Cunningham, J., Geller, N.L., Bosl, G.J. and Kramer, B.S. (1994). After the cisplatin breakthrough: a comparison of trial and population based data for advanced

testicular cancer. Journal of Clinical Oncology 12:368-377.

Follmann, D.A., Proschan, M.A. and Geller, N.L. (1994). Monitoring pairwise comparisons in multiarmed clinical trials. Biometrics 50:325-336.

Follmann, D.A., Wu, M. and Geller, N.L. (1994). Testing treatment efficacy in clinical trials with repeated binary measurements and missing observations. Communications in Statistics Part A: Theory and Methods 23:557-574.

Geller, N.L. (1994). Discussion of "Interim analysis: the Alpha Spending Function approach" by D.L. DeMets. Statistics in Medicine 13:1353-1356.

Hunsberger, S., Sorlie, P. and Geller, N.L. (1994). Stochastic curtailing and conditional power in matched case-control studies. Statistics in Medicine 13:663-670.

Knatterud, G.L., Bourassa, M.G., Pepine, C.J., Geller, N.L., Sopko, G., Chaitman, B.R., Pratt, C., Stone, P.H., Davies, R.F., Rogers, W.J., Deanfield, J.E., Goldberg, A.D., Ouyang, P., Mueller, H., Sharaf, B., Day, P., Selwyn, A.P., Conti, C.R. (1994). Effects of treatment strategies to suppress ischemia in coronary artery disease patients: 12 week results of the asymptomatic cardiac ischemia pilot (ACIP). Journal of the American College of Cardiology 24:11-20.

McMahon, R., Proschan, M.A., Geller, N.L., Stone, P., Sopko, G. (1994). Sample size calculation for clinical trials in which entry criteria and outcomes are counts of events. Statistics in Medicine 13:859-870.

Pepine, C.J., Geller, N.L., Knatterud, G.L., Bourassa, M.G., Chaitman, B.R., Davies, R.F., Day, P., Deanfield, J.E., Goldberg, A.D., McMahon, R.P., Mueller, H., Ouyang, P., Pratt, C., Proschan, M., Rogers, W.J., Selwyn, A.P., Sharaf, B., Sopko, G., Stone, P.H., C.R. Conti (1994). The asymptomatic cardiac ischemia pilot (ACIP): design of a randomized clinical trial, baseline data and implications for a long-term outcome trial. Journal of the American College of Cardiology 24:1-10.

Proschan, M.A., Follmann, D.A. and Geller, N.L. (1994). Monitoring multiarmed trials. Statistics in Medicine 13: 1441-1452.

Amorosa, J.K., Laraya-Cuasay, L.R., Sohn, L., Loeb, D.M., Geller, N., Stylianou, M., and Nosher, J.L. (1995). Radiologic diagnosis of cystic fibrosis in adults and children. Academic Radiology 2:222-225.

Bourassa, M.G., Knatterud, G.L., Pepine, C.J., Sopko, G. Rogers, W.J., Geller, N.L., Dyrda, I., Forman, S.A., Chaitman, B.R., Sharaf, B., Davies, R.F., Conti, C.R. for the ACIP Investigators (1995). Asymptomatic cardiac ischemia pilot (ACIP) study: improvement of cardiac ischemia at one year following PTCA and CABG. Circulation 92:II-1-II-7.

Conti, C.R., Bourassa, M.S., Chaitman, B.R., Geller, N.L., Knatterud, G.L., Pepine, C.J., Pratt, C. and Sopko, G. (1995). Asymptomatic Cardiac Ischemia Pilot (ACIP). Transactions of the American Clinical and Climatological Association CVI: 77-84.

Freedman, L.S., Simon, R., Foulkes, M., Friedman, L., Geller, N.L., Gordon, D. and Mowery, R. (1995). Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 - the perspective of NIH clinical trialists. Controlled Clinical Trials 16:277-285.

Freedman, L.S., Simon, R., Foulkes, M., Friedman, L., Geller, N.L., Gordon, D. and Mowery, R. (1995). Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 - the perspective of NIH clinical trialists: response to discussants letters. Controlled Clinical Trials 16:310-312.

Geller, N.L., Proschan, M.A. and Follmann, D.A. (1995). Group sequential monitoring of multi-armed clinical trials. Drug Information Journal 29:705-713.

Rogers, W.J., Bourassa, M.G., Andrews, T., Bertolet, B.D., Blumenthal, R.S., Chaitman, B., Forman, S., Geller, N.L., Goldberg, A.D., Habib, G.B., Masters, R.G., Moisa, R.B., Mueller, H., Pearce, D., Pepine, C., Sopko, G., Steingart, R.M., Stone, P.H., Knatterud, G.L., Conti, C.R. for the ACIP Investigators (1995). The asymptomatic cardiac ischemia pilot study (ACIP): outcome at one year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. Journal of the American College of Cardiology 26:594-605.

Campeau, L., Knatterud, G., White, C., Domanski, M., Geller, N.L., Rosenberg, Y. and the Post-CABG Clinical Trial Investigators (1996). The NHLBI post-coronary artery bypass graft clinical trial (Post-CABG): Angiographic Outcomes. In: Developments in Cardiovascular Medicine 180:203-214, Lipid-lowering Therapy and Progression of Coronary Atherosclerosis, AVG Bruschke, JHC Reiber, KI Lie, and Hjj Wellens, eds. Kluwer Academic Publishers, Dordrecht, Boston, London.

Caracciolo, E.A., Chaitman, B.R., Forman, S.A., Stone, P.H., Bourassa, M.G., Sopko, G., Geller, N.L. and Conti, C.R. (1996). Diabetics with coronary disease have a similar prevalence of asymptomatic ischemia during exercise treadmill testing and ambulatory ischemia monitoring compared to non-diabetic patients: an ACIP database study. Circulation 93:2097-2105.

The Digitalis Investigation Group (includes N. Geller) (1996). Rationale, design, implementation and baseline characteristics of patients in the DIG trial: a large, simple trial to evaluate the effect of digitalis on mortality in heart failure. Controlled Clinical Trials 17:77-97.

Geller, N.L. (1996). Role of meta-analysis in design and monitoring of randomized clinical trials: summary of first day of the workshop. Statistics in Medicine 15:1313-1315.

Geller, N.L., Freedman, L., DerSimonian, R. and Lee, Y.-J. (1996). Guest Editors of "Proceedings of Workshop on the roles of meta-analysis in design and monitoring of randomized clinical trials." Statistics in Medicine Vol. 15. No. 12.

Geller, N.L. and Proschan, M.A. (1996). Meta-analysis: a consumer's guide. Journal of Biopharmaceutical Statistics 6:377-394.

Pepine, C.J., Andrews, T., Forman, S., Geller, N.L., Hill, J.A., Pratt, C., Rogers, W.J., Steingart, R., Sopko, G., Stone, P.H., Conti, C.R. (1996). Relationship of patient characteristics to cardiac ischemia during daily life activity: an ACIP data bank study. The American Journal of Cardiology 77:1267-1272.

Pepine, C.J., Bourassa, M.G., Chaitman, B.R., Conti, C.R., Geller, N.L., Knatterud, G.L., Pratt, C.M., Rogers, W.J. and Sopko, G. for the ACIP Investigators (1996). Letter to the Editor. Journal of the American College of Cardiology 28:1315-1318.

Pratt, C.M., McMahon, R.C., Goldstein, S., Pepine, C.J., Andrews, T.C., Dyrda, I., Frishman, W., Geller, N.L., Hill, J.A., Morgan, N.A., Stone, P.H., Knatterud, G.L., Sopko, G., Conti, C.R. for the ACIP

Investigators (1996). The asymptomatic cardiac ischemia pilot (ACIP) study: comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia. The American Journal of Cardiology 77:1302-1309.

Tilley, B.C., Marler, J., Geller, N., Lu, M. Legler, J., Ryan, L. and Grotta, J. (1996). Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA stroke trial. Stroke 27:2136-2141. <<http://stroke.ahajournals.org/cgi/content/full/27/11/2136>>

Canner, P.L. Thompson, B., Knatterud, G.L., Geller, N., Campeau, L. and Zucker, D. (1997). An application of the Zucker-Wittes modified ratio estimate statistic in the Post-CABG clinical trial. Controlled Clinical Trials 18:318-327.

Conti, C.R., Geller, N.L. Knatterud, G., Forman, S., Pratt, C., Pepine, C.J. and Sopko, G. for the ACIP Investigators (1997). Definitions of angina status and prediction for cardiac events in patients with coronary artery disease enrolled in the asymptomatic cardiac ischemia pilot (ACIP). The American Journal of Cardiology 79:889-892.

Davies, R.F., Goldberg, A.D., Forman, S., Pepine, C.J., Knatterud, G.L., Geller, N.L., Sopko, G., Pratt, C., Deanfield, J. and Conti, C.R. for the ACIP investigators (1997). Asymptomatic cardiac ischemia pilot (ACIP) study two year follow up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 95:2037-2143.

The Digitalis Investigation Group (includes N. Geller) (1997). The effect of Digoxin on mortality and morbidity in patients with heart failure. The New England Journal of Medicine 336:525-533.

Ellenberg, J., Gail, M. and Geller, N.L. (eds.) (1997). Conversations with NIH Biostatisticians: Interviews with the pioneers of biostatistics at the National Institutes of Health. Statistical Science 12:77-131.

Geller, N.L. (1997). A conversation with Tavia Gordon. Statistical Science 12:113-118.

Mulcahy, D., Hussain, S., Zalos, G., Rehman, A., Andrews, N.P., Schenke, W.H., Geller, N.L. and Quyyuymi, A.A. (1997). Long-term prognostic significance of ambulatory ischemia in predominantly low-risk patients with stable coronary disease: importance of conventional risk stratification and influence of plaque progression. Journal of the American Medical Association 277:318-324.

O'Brien, P.C. and Geller, N.L. (1997). Interpreting tests for efficacy in clinical trials with multiple endpoints. Controlled Clinical Trials 18:222-227.

Pepine, C.J., Sharaf, B., Andrews, T., Forman, S., Geller, N., Knatterud, G., Mahmarian, J., Ouyang, P., Rogers, W.J., Sopko, G., Steingart, R., Stone, P.H. and Conti, C.R. for the ACIP Study Group (1997). Relation between clinical, angiographic and ischemia findings at baseline and ischemia-related adverse outcomes at one year in the Asymptomatic Cardiac Ischemia Pilot trial. Journal of the American College of Cardiology 29:1483-1489.

The Post Coronary Artery Bypass Graft (POST-CABG) Trial Investigators (includes N. Geller as member of Writing Committee) (1997). The effect of aggressive LDL cholesterol lowering and low dose anticoagulation on obstructive changes in saphenous vein coronary bypass grafts. The New England Journal of Medicine 336:153-162.

McMahon, R.P., Waclawiw, M.A., Geller, N.L., Baron, F.B., Terrin, M.L. and Bonds, D.R. (1997). An extension of Stochastic curtailment for incompletely reported and classified recurrent events: the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH). Controlled Clinical Trials 18:420-430.

Geller, N.L. and Friedman, L. (1998). Cooperative heart disease clinical trials sponsored by the National Heart, Lung, and Blood Institute (NHLBI). Encyclopedia of Biostatistics, John Wiley & sons, New York and Chichester, 941-950.

Geller, N.L. and O'Brien, P. (1998). Simultaneous inference (Multiplicity problem). Encyclopedia of Biostatistics, John Wiley & sons, New York and Chichester, 4116-4120.

Handberg-Thurmond, E., Baker, A., Grichen, S. Coglianesi, M.E., Barry, J. Dukes, G., Byers, S., Dvorak, L., Estob, J., Francis, M., Kolb, R., MacCallum, G., Townsend, S., Whittom, L., Hemingway, K., Forman, S., Pepine, C.J., Geller, N., Chairman, B., and Conti, C.R. (1998). High yield sources to identify patients with asymptomatic cardiac ischemia. Clinical Cardiology 21:177-182.

Pfeffer, M., Domanski, M., Rosenberg, Y., Verter, J., Geller, N., Albert, P., Hsia, J. and Braunwald, E. (1998). Prevention of events with angiotensin-converting enzyme inhibition (The PEACE study design). The American Journal of Cardiology 82:25H-30H.

Buyse, M., George, S.L., Evans, S., Geller, N.L., Ranstam, J., Scherrer, B., Lesaffre, E., Murray, G., Edler, L. Hutton, J., Colton, T., Lachenbruch, P., Verma, B.L. for the ISCB Subcommittee on Fraud (1999). The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Statistics in Medicine 18:3435-3451.

Campeau, L., Hunninghake, D.B., Knatterud, G.L., White, C.W., Domanski, M., Forrester, J.S., Geller, N.L., Gobel, F.L., Herd, J.A., Hoogwerf, B.J., Rosenberg, Y. and the Post CABG Investigators (1999). Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, in the elderly and in patients with risk factors: NHLBI Post CABG clinical trial. Circulation 99:3241-3247.

Domanski, M.J., Exner, D.V., Borkowf, C.B., Geller, N.L., Rosenberg, Y., Pfeffer, M.A. (1999). Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: a meta-analysis of randomized clinical trials. Journal of the American College of Cardiology 33:598-604.

Geller, N.L. (1999). Commentary on “Redesign of trials under different enrollment mixes” by Curtis L. Meinert. Statistics in Medicine 18:253-254.

Gu, M., Follmann, D. and Geller, N.L. (1999). Monitoring a general class of two-sample survival statistics with applications. Biometrika 86:45-58.

Hoogwerf, B.J., Waness, K., Cressman, M., Canner, J., Campeau, L., Domanski, M., Geller, N., Herd, A., Hickey, A., Hunninghake, D.B., Knatterud, G., White, C. for the Post-CABG Study Investigators (1999). Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes mellitus: Post Coronary Artery Bypass Graft trial. Diabetes 48:1289-1294.

Tang, D.-I. and Geller, N.L. (1999). Closed testing procedures for group sequential clinical trials with multiple endpoints. Biometrics 55:1188-1192.

Thompson, B., Geller, N., Hunsberger, S., Hill, R., Kaufmann, P., Bielory, L., Freedman, R.R., Jacob, R.G., Smith, E.A., Wigley, F.M. (1999). Designing clinical trials with behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials 20:52-63.

Domanski, M.J., Borkowf, C.B., Campeau, L., Hunninghake, D., Knatterud, G.L., White, C., Rosenberg, Y., Geller, N.L. and the Post-CABG Investigators (2000). Prognostic factors for atherosclerosis progression in saphenous vein grafts: the Post-Coronary Artery Bypass Graft (Post-CABG) trial. Journal of the American College of Cardiology 36:1877-1883.

Hasegawa, R.P., Blitz, A., Geller, N.L., Goldberg, M.E. (2000). Neurons in monkey prefrontal cortex that track past or predict future performance. Science 290:1786-9.

Knatterud, G.L., Rosenberg, Y., Campeau, L., Geller, N.L., Hunninghake, D.B., Forman, S.A., Forrester, J.S., Gobel, F.L., Herd, J.A., Hickey, A., Hoogwerf, B.J., Terrin, M.L., White, C. and the Post-CABG Investigators (2000). The long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation in the POST Coronary Artery Bypass Graft trial. Circulation 102:157-165. <<http://circ.ahajournals.org/cgi/content/full/102/2/157>> (Editorial: <<http://circ.ahajournals.org/cgi/content/full/102/2/144>>)

Ranstam, J., Buyse, M., George, S.L., Evans, S., Geller, N.L., Scherrer, B., Lesaffre, E., Murray, G., Edler, L., Hutton, J., Colton, T., Lachenbruch, P. (2000). The biostatistician's view on fraud in medical research. Controlled Clinical Trials 21:415-427.

Proschan, M.A., McMahon, R.P., Shih, J.H., Hunsberger, S.A., Geller, N.L., Wittes, J. and Knatterud, G. (2001). Statistical properties of the Wittes, Lakatos, and Probstfield imputation method in clinical trials. Journal of Statistical Planning and Inference 96:155-165.

Tisdale, J.F., Dunn, D.E., Geller, N., Plante, M., Nunez, O., Dunbar, C.E., Barrett, A.J., Walsh, T.J., Rosenfeld, S.J., Young, N.S. (2000). High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. The Lancet 356:1554-1559.

Wigley, F.M., Wise, R., Haythornthwaite, J., Rand, C., Smith, E.A., Maricq, H.R., Middaugh, S., Silver, R.M., Valter, I., Allenback, G., Arnold, J., Steedman, S., Risinger, A., King, A., Bielory, L., Attanasio, V., Tarantola, J., Centeno, L., Jacob, R.G., Medsger, T., Jennings, R., Scheier, M., Vaughan, C., Wasko, M.C., Steen, V.D., Dunbar-Jacob, J., Tamres, L., Freedman, R.R., Mayes, M.D., Brejnak, C., Tindall, C., Bielory, L., Thompson, B., Frederick, M., Canner, M., Canner, J., Canner, P., Shaffer, T.R., Hill, D.R., Kaufmann, P.G., Czajkowski, S., Geller, N., Hunsberger, S., Jennings, C., Stevens, W.M., Hess, E.V., Corson, J.A., Jobe, J.B., Smith, H., Tilley, B. (2000). Comparison of sustained-release Nifedipine and temperature biofeedback for treatment of primary Raynaud's phenomenon: Results of a randomized trial with one year follow-up. Archives of Internal Medicine 160:1101-1108.

White, C.W., Gobel, F.L., Campeau, L., Knatterud, G., Forman, S., Forrester, J.S., Geller, N.L., Herd, A., Hickey, A., Hooverf, B.J., Hunninghake, D.B., Rosenberg, Y., Terrin, M.L., and the Post CABG Investigators (2001). Effect of an aggressive lipid lowering strategy on the progression of atherosclerosis in the left main coronary artery from patients in the Post Coronary Artery Bypass Graft Trial. Circulation 104:2660-2665.

Maciejewski, J.P., Ristiano, A.M., Sloand, E.M., Wisch, L., Geller, N., Barrett, J.A., Young, N.S. (2002). A pilot study of the soluble recombinant tumor necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. British Journal of Haematology 117: 119-126.

Thompson, B., Jacob, R., Frederick, M., Geller, N., Hunsberger, S. (2002). Innovative designs in behavioural trials. Statistics in Medicine 19:2981-2989.

Bauer, P., Chi, F., Geller, N., Gould, L., Jordan, D., Mohanty, S., O'Neill, R. and Westfall, P. (2003). Industry, government and academic panel discussion on multiple comparisons in a "real" phase three clinical trial. (Edited by Peter H. Westfall, Nancy Geller and Ajit Tamhane) Journal of Biopharmaceutical Statistics 13:691-701.

Collins, J.F., Egan, D., Yusuf, S., Garg, R., Williford, W. Geller, N. on behalf of the Digitalis Investigation Group (DIG) Investigators (2003). Overview of the DIG trial. Controlled Clinical Trials 24:269S-276S.

Egan, D., Geller, N., Yusuf, S., Garg, R., Collins, J. on behalf of the Digitalis Investigation Group (DIG) investigators (2003). Lessons learned from the Digitalis Investigations Group (DIG) trial. Controlled Clinical Trials 24:316S-326S.

Knatterud, G.L., White, C., Geller, N.L., Campeau, L., Forman, S.A., Domanski, M., Forrester, J.S., Gobel, F.L., Herd, J.A., Hickey, A., Hoogwerf, B.J., Hunninghake, D.B., Terrin, M.L., Rosenberg, Y. and the post-CABG Investigators (2003). Angiographic changes in saphenous vein grafts are predictors of clinical outcomes. American Heart Journal 145:262-269.

Kwong, R.Y., Schussheim, A.E., Rekhraj, S., Aletras, A.H., Geller, N., Davis, J., Christian, T.F., Balaban, R.S. and Arai, A.E. (2003). Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. Circulation 107:531-537. <<http://circ.ahajournals.org/cgi/reprint/107/4/531.pdf>>

Carvalho, C., Geller, N., Kurlander, R., Srinivasan, R., Mena, O., Griffith, L., Linehan, W.M. and Childs, R.W. (2004). Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. Blood 103: 1560-1563.

Corley, S.D., Epstein, A.E., DiMarco, J.P., Domanski, M.J., Geller, N., Greene, H.L., Josephson, R.A., Kellen, J.C., Klein, R.C., Krahn, A.D., Mickel, M., Mitchel, L.B., Nelson, J.D., Rosenberg, Y., Schron, E., Shemanski, L., Waldo, A.L., Wyse, D.G., for the AFFIRM Investigators (2004). Relationships between sinus rhythm, treatment and survival: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109:1509-13.

Ganesh, S.K., Skelding, K.A., Mehta, L., O'Neill, K., Joo, J., Zheng, G., Goldstein, J., Simari, R. Billings, E., Geller, N.L., Holmes, D., O'Neill, W.W., Nabel, E.G. (2004). Rationale and study design of the CardioGene study: genomics of in-stent restenosis. Pharmacogenomics.5:949-1004.

Geller, N.L., Sorlie, P., Coady, S., Fleg, J., Friedman, L. (2004). Limited access data sets from studies funded by the National Heart, Lung and Blood Institute. Clinical Trials 1:517-524.

The PEACE Investigators (includes N. Geller as member of Writing Committee). (2004). Effects of angiotensin converting enzyme inhibition in patients with stable coronary artery disease: the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial. New England Journal of Medicine 351:2058-2068.

Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D, Donohue T, Shalabi R, Carvallo C, Barrett AJ, Geller N, Childs R. (2004). Improved survival in steroid-refractory acute graft versus host disease after non-myceloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. . British Journal of Haematology 124:777-786.

Curtis, A.B., Gersh, B.J., Corley, S.D., DiMarco, J.P., Domanski, M.J., Geller, N., Greene, H.L., Kellen, J.C., Mickel, M., Nelson, J.D., Rosenberg, Y., Schron, E., Shemanski, L., Waldo, A.L., Wyse, D.G. for the AFFIRM Investigators. (2005). Clinical factors that influence response to treatment strategies in atrial fibrillation: the AFFIRM study. American Heart Journal 149:645-649.

Geller, N.L., Editor (2005). Advances in Clinical Trial Biostatistics. Marcel Dekker, Inc., New York and Basel.

Geller, N.L. (2005). On multiple endpoints in clinical trials. Chapter 6 in: Advances in Clinical Trial Biostatistics, Nancy L. Geller, ed. Marcel Dekker, Inc., New York and Basel, 101-119.

Geller, N.L., Follmann, D.F., Leifer, E.S. and Carter, S.L. (2005). Design of early trials in peripheral blood stem cell transplantation: a hybrid frequentist-Bayesian approach. Chapter 2 in: Advances in Clinical Trial Biostatistics, Nancy L. Geller, ed. Marcel Dekker, Inc., New York and Basel, 40-52.

Geller, N.L. and Friedman, L. (2005). Cooperative heart disease trials. Encyclopedia of Biostatistics, Peter Armitage and Theodore Colton, Eds. John Wiley & sons, New York and Chichester, Vol II, 1169-1180.

Geller, N., Sorlie, P., Coady, S., Fleg, J., Manolio, T., Friedman, L. (2005). Letter to the Editor concerning update of policy described in "Limited access data sets from studies funded by the National Heart, Lung and Blood Institute" (Clinical Trials 1:517-524, 2004). Clinical Trials 2:538.

Gorak, E., Geller, N., Srinivasan, R., Espinoza-Delgado, I, Donohue, T, Barrett, AJ, Suffredini, A, Childs, R. (2005). Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. Biology of Blood and Marrow Transplantation 7:542-550.

Joo, J., Tian, X., Zheng, G., Lin, J.-P., Geller, N. Selection of SNPs in Disease Association Data (2005). Genetic Analysis Workshop 14. Biomed Central Genetics 6 (Supplement 1): S93.

Srinivasan,R., Balow,J.E., Sabnis, Lundqvist, S.A., Igarashi, T.,Takahasi, Y., Austin, H., Tisdale, J., Barrett, J. Geller, N., Childs, R. (2005). Nephrotic Syndrome: An under-recognised immune-mediated complication of nonmyeloablative allogeneic haematopoietic cell transplantation. British Journal of Haematology 131:74-79.

Zheng, G., Joo, J., Ganesh, S., Nabel, E., Geller, N.L. (2005). On averaging power for genetic association and linkage studies. Human Heredity 59:14-20.

Altmaier, E.M., Ewell, M., McQuellon, R., Geller, N., Carter, S. L., Henslee-Downey, J., Davies, S., Papadopolous, E., Yanovich, S. and Gingrich, R. (2006). The effect of unrelated-donor marrow transplantation on health-related quality of life: A report of the unrelated donor marrow transplantation trial (T-cell depletion trial). Biology of Blood and Marrow Transplantation 12:648-655.

Ingkanisorn, W.P., Kwong, R.Y., Bohme, N.S., Geller, N.L., Rhoads, K.L., Dyke, C.K., Paterson, I., Syed, M.S., Aletras, A.H., and Arai, A.E. (2006). Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. Journal of the American College of Cardiology 47:1427-32.

Srinivasan, R., Takahasi, Y., McCoy, J.P., Espinoza-Delagado, I., Dorrance, C. Igarashi, T., Lundqvist, A., Barrett, A.J., Young, N.S., Geller, N., Childs, R.W. (2006). Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. British Journal of Hematology 133:305-314.

Anderson, G.L., Kooperberg, C., Geller, N., Rossouw, J.E., Pettinger, M., and Prentice, R.L. (2007). Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials. Clinical Trials 4:207-217.

Joo, J., Tian, X., Zheng, G., Stylianou, M., Lin, J.-P., Geller, N.L. (2007). Joint analysis of case-parent trio and unrelated case-control designs in large scale association studies. Genetic Analysis Workshop 15. BMC Proceedings 1(Supplement 1): S28.

Zheng, G., Joo, J., Zhang, C., Geller, N.L. (2007). Testing association for markers on the X chromosome. Genetic Epidemiology 31: 834-843.

Zheng, G., Joo, J., Lin, J.-P., Stylianou, M., Waclawiw, M.A., Geller, N.L. (2007). Robust ranks of true associations in genome-wide case-control association studies. Genetic Analysis Workshop 15. BMC Proceedings 1(Supplement 1):S165.

Borer J.S., Gordon, D.J., and Geller, N.L. (2008). When Should Data and Safety Monitoring Committees Share Interim Results in Cardiovascular Trials? Journal of the American Medical Association 299:1710-1712.

Geller, N.L. (2008). Discussion on "Second-guessing clinical trial designs" by J.J. Shuster and M.N. Chang. Sequential Analysis 27:41-45.

Hsia, J., Jablonski, K.A., Rice, M.M., Sabatine, M.S., Zabalgoitia, M., Maggioni, A., Cuddy, T.E., Domanski, M.J., Geller, N.L., Flaker, G., Solomon, S., Olmland, T. and Rouleau, J. for the PEACE investigators (2008). Sudden cardiac death in patients with stable coronary disease and preserved left ventricular function. The American Journal of Cardiology 101:457-461.

Logan, B.R., Leifer, E., Ewell, M., Horowitz, M.M., Carter, S., Bredeson, C., Geller, N. (2008). Use of biological assignment in hematopoietic stem cell transplantation clinical trials. Clinical Trials 5:607-16.

Takahashi, Y., Harashima, N., Kajigaya, S., Yokoyama, H., Cherkasova, E., McCoy, J.P., Hanada, K., Mena, O., Kurlander, R., Abdul, T., Srinivasan, R., Lundqvist, A., Malinzak, E., Geller, N. Lerman, M.I., and Childs, R.W. (2008). Regression of human kidney cancer following allogeneic stem cell transplantation is associated with T cells recognizing A HERV-E antigen. Journal of Clinical Investigation 118: 1099-1109.

Zannad, F., Stough, W.G., Pitt, B., Cleland, J.G.F., Kirkwood, R.A., Geller, N.L., Torp-Pedersen, C., Kirwan, B.-A., Follath, F. (2008). Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. European Heart Journal 29:413-421.

Tian, X., McKinlay, S. and Geller, N.L. (2009.) Setting sample size for randomized clinical trials. In *Successful Randomized Trials: A Handbook for the 21st Century*, Michael Domanski, and Sonja McKinlay, eds., 45-70.

Zheng, G., Joo, J., Tian, X., Wu, C.O., Lin, J.-P., Stylianou, M., Waclawiw, M.A., and Geller, N.L. (2009). Robust genome-wide scans with genetic model selection using case-control design. Statistics and its Interface 2:145-151.